Lion/Gem Luxembourg 3 S.a.r.l. Announces Fourth Quarter and Full Year Results for FY 2017
The Fourth Quarter and full year results for FY17 for Lion/Gem Luxembourg 3 S.a.r.l. (associated with Young’s Seafood Limited) will be made available on our Investor Relations website on January 26, 2018. The Fourth Quarter and full year results FY17 call for investors that accompanies this information is scheduled to take place at 13:00 GMT on January 26, 2018. The Fourth Quarter covers the quarter to September 30 2017; the financial year end for Lion/Gem Luxembourg 3 S.a.r.l. is September 30, 2017.
For further information:
If you are an investor or a potential investor in the 8¼%/ 9% Senior PIK Notes due 2019, of Lion/Gem Luxembourg 3 S.a.r.l., and would like access to this information, please register your interest on our Investor Relations website: https://youngsseafood.co.uk/investors/ .
If you have any questions about the registration process or need further information, please do not hesitate to contact Nicholas Donnelly, Communications Manager at Young’s Seafood:
This announcement contains inside information by Lion/Gem Luxembourg 3 S.a.r.l. under Regulation (EU) 596/2014 (16 April 2014).
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
PRICE-F(X)17.12.2018 08:10 | Pressemeddelelse
Price f(x) Files Petitions with US Patent and Trademark Office to Invalidate Vendavo’s Patents and Launches a Counter Lawsuit
ABB17.12.2018 07:18 | Pressemeddelelse
ABB: Shaping a leader focused in digital industries
AURAK15.12.2018 11:51 | Pressemeddelelse
AURAK Gains SACSCOC Accreditation
KRAMER-LEVIN14.12.2018 18:44 | Pressemeddelelse
Lehman Brothers Treasury Announces Plans for Partial Wind-Down
MA-TAKEDA-PHARMACEUTICAL14.12.2018 18:02 | Pressemeddelelse
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD
FL-POTNETWORK-HOLDINGS14.12.2018 16:44 | Pressemeddelelse
Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum